Elicio Therapeutics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Elicio Therapeutics Inc 's ROA in the second quarter of 2026?
Elicio Therapeutics Inc recorded a cumulative net loss of $-38 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -139.14%.

However, within the Healthcare sector 798 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4405, from total ROA ranking in the first quarter of 2026 at 5068.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	8.22 %	-19.38 %	4.38 %	-18.65 %	170.45 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-38	-40	-40	-46	-55
Return On Assets (TTM)	-139.14 %	-151.12 %	-141.56 %	-165.65 %	-186.36 %
ELTX's Total Ranking	# 4405	# 5068	# 4538	# 4648	# 4730
Total Assets (TTM) in million	32	23	26	28	30
Seq. Total Assets Change	40.83 %	-12.27 %	-8.56 %	-4.21 %	4.92 %
Seq. Net Income Change	-	-	-	-	-

ELTX's 5 Years Annual ROA >> Back to ELTX Management Effectiveness >> Compare ELTX ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 375
Sector	# 799
Overall	# 4338

Return On Assets Statistics
High	Average	Low
-8.61 %	-106.95 %	-194.38 %
(Sep 30 2022)		(Dec 31 2024)

News about Elicio Therapeutics Inc Return on Assets ROA

At the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting, Elicio Therapeuti...

Targeted Immunotherapy Progress: Elicio Therapeutics ELI-002 Demonstrates Promising Results in Combating KRAS Mutations At the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting, Elicio Therapeutics shared compelling translational data from the Phase 1 AMPLIFY-7P study of their investigational agent, ELI-002. Initial findings from this ongoing study indicate that ELI-002 elicits potent and sustained T cell responses against KRAS mutations and patient-specific neoantigens, showcasing its potential as a significant advancement in precision oncology. KRAS mutations are among the most prevalent oncogenic drivers in various malignancies, including pancreatic, colorectal, and lung cancers. Challenges in targeting KRAS mutations have made them a critical focus of cancer research. Elicio Therapeutics has developed ELI-002, a lymph node-targeted therapeutic platform aiming to harness the body s immune system to detect and eradicate cancer cells harboring these elusive mutations.

Elicio Therapeutics Announces Proposed Public Offering to Expand Pipeline of Novel Immunotherapies for Cancer Treatment

BOSTON, June 27, 2024 - Elicio Therapeutics, Inc. (Nasdaq: ELTX) has taken a significant step towards advancing its clinical-stage biotechnology portfolio with the announcement of a proposed public offering. As a pioneer in the development of innovative immunotherapies for cancer treatment, Elicio aims to leverage this offering to further accelerate the advancement of its pipeline.
The underwritten public offering includes shares of Elicio s common stock along with accompanying common warrants. Additionally, certain investors will have the option to acquire pre-funded warrants for the purchase of common stock and accompanying common warrants. All of the common stock, pre-funded warrants, and accompanying common warrants will be offered by Elicio. However, the completion of this offering, its actual size, and specific terms are dependent on market and other conditions, leaving room for uncertainties.

Financial Statements
Elicio Therapeutics Inc 's Assets	$ 32 million	ELTX's Balance sheet
Elicio Therapeutics Inc 's Income	$ -8 million	Quarterly ELTX's Income Statement
ELTX's Income by Division		See ELTX's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	4.38 %	8.2 %	-66.37 %	-27.32 %	-
Total Assets in million	26	25	23	68	94
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-40	-52	-35	-39	-55
Annual Return On Assets	-153.01 %	-209.47 %	-153.7 %	-56.99 %	-58.24 %

ELTX's 5 Years Annual ROA >> Back to ELTX Management Effectiveness >> Compare ELTX ROA to its Competitors

More Return On Assets Ratios
ELTX's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ELTX's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ELTX's Competitors
Subscribers only: Roa for Elicio Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for ELTX's Customers

You may also want to know
ELTX's Roi	ELTX's Inventory Turnover Ratio	ELTX's Growth Rates	ELTX's Dividend Comparisons
	ELTX's Profitability Ratios	ELTX's Asset Turnover Ratio	ELTX's Dividend Growth
ELTX's Roe	ELTX's Valuation Ratios	ELTX's Financial Strength Ratios	ELTX's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-26T07:39:24+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.